Synthetic peptides incorporating the derived amino acid sequence of VP2 residues 156 to 170 of human rhinovirus type 2 (HRV2) have previously been shown to elicit antibodies that neutralize virus infectivity. The proportion of virus-reactive antibodies present in polyclonal antisera to these peptides is, however, very low. Moreover, neutralization titrations of such antisera correlate poorly with other assays of either anti-virus or anti-peptide activity, suggesting the presence of antibodies with different specificities. To investigate these findings further, we produced a panel of monoclonal antibodies (MAbs) to VP2 peptides of residues 156 to 170 and characterized their reactions with a range of antigens in ELISA, precipitation and neutralization titrations. All the MAbs obtained recognized the homologous peptide, but could be divided into four main reaction groups according to their specificity for viral antigens. Antibodies in the first group recognized and neutralized native virus, apparently by preventing attachment to cells. A second group of MAbs bound to intact particles with similar affinities to the first group, but failed to neutralize infectivity. Antibodies in the third group recognized virus only after capsid distortions incurred by heating or by previous reaction with polyclonal antibodies. The fourth group comprised MAbs that were mainly peptide-specific. Some possible applications of anti-peptide MAbs to improving the design of peptide immunogens are considered.
Introduction
During the past decade it has become evident that the majority of neutralizable epitopes on the surface of picornaviruses are dependent on the quaternary structure of the particle. This was suggested initially as a result of mapping the amino acids contributing to monoclonal antibody (MAb) binding sites, either by the identification of substitutions in the protein sequences that conferred antibody resistance or by peptide binding studies. Subsequent corroboration was provided by resolution of the molecular structure of representatives of each of the four genera of the Picornaviridae by X-ray crystallography (Rossmann et al., 1985; Hogle et al., 1985; Luo et al., 1987; Acharya et al., 1989) . The structural studies confirmed that antigenically important residues, both linearly distant on the same protein or on separate proteins, are juxtaposed in the assembled particle. In some cases, however, these residues cluster t Present address: Department of Immunology, AFRC Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Woking, Surrey GU24 0NF, U.K. sufficiently closely on the primary sequence for peptides synthesized to these regions to bind and induce antiviral antibodies. Such peptides have, therefore, been evaluated as potential vaccines for a number of picornaviruses as a means of overcoming both the inherent disadvantages of conventional vaccines (Brown, 1988) and some of the problems resulting from antigenic diversity (Parry et al., 1989; Jameson et al., 1985) . Antiviral responses to peptide immunogens have been extremely variable. The greatest progress has probably been achieved using peptides corresponding to the surface-exposed G-H loop of VP1 of foot-and-mouth disease virus (FMDV), which can elicit a neutralizing antibody response (Bittle et al., 1982; Pfaff et al., 1982) that is protective in target species (DiMarchi et al., 1986) . Approximately 35 % of the antibodies induced by these peptides in laboratory animals also recognize virus (Parry et al., 1988) but, even so, the levels of protection attained in target species have been inconsistent. The effectiveness of FMDV peptides in mimicking the immunogenicity of the G-H loop is probably due to the region's unusually flexible nature in the native particle (Acharya et al., 1989; Parry et al., 1990) . The more constrained antigenic structures found in other picorna-viruses appear to limit this potential for antigenic mimicry with peptides. Studies with peptides to poliovirus, for example, resulted in neutralizing responses that were either of generally low titre or were limited to only a few of the animals vaccinated (Ferguson et In this paper we report a detailed analysis of the humoral response to a linear immunogenic tract in isolation by the production and characterization of MAbs raised against peptides containing residues 156 to 170 of HRV2 VP2. These MAbs could be classified into four major groups on the basis of their antigen specificity, with neutralizing antibodies being in the minority. The properties of the antibodies that might influence neutralizing ability are considered, and their potential application for improving the design of novel immunogens is discussed.
Methods
Peptides. Two peptides, corresponding to the collinear sequences of HRV2 VP2 amino acids 156 to 170 with homologous T cell epitopes comprising either VP1 residues 150 to 156 (peptide 1) or VP2 residues 24 to 33 (peptide 2) , were synthesized by conventional Merrifield t-Boc chemistry using the method of Houghten (1985) . Both peptides had an additional 'unnatural' cysteine residue introduced at their C termini. For assay purposes, peptides corresponding to the B and two T cell epitopes individually were also produced.
Monoclonal antibodies. BALB/c mice were immunized by the intramuscular inoculation of 100 to 200 gg of oil-adjuvanted peptide, followed 2 to 3 months later by a secondary intravenous dose of 100 to 150 mg of non-adjuvanted peptide, both without any carrier molecule. Hybridoma cell lines were obtained by fusing spleen cells from these mice, recovered 3 days after the second inoculation, with NS0 mouse myeloma cells using PEG 1500 (BDH) and the technique described by McMaster & Williams (1979) . The hybridomas were grown in RPMI 1640 medium (Flow) containing 10% fetal calf serum, 2mM-Lglutamine, HAT supplement and antibiotics in 24 x 2 ml Costar plates. Following two successive changes of half the medium in each well during the second week of in vitro culture, samples were withdrawn for testing both by indirect ELISA against peptide and sandwich ELISA against virus. Individual cell colonies were picked from positive wells, and monoclonal lines were established from these by cloning single cells twice at limiting dilution. Large volume pools of supernatant medium from the monoclones were concentrated approximately 20-fold by ultrafiltration through Diafto XM-50 membranes, and the concentrates were used for antibody characterization studies.
Isotyping. Antibody class and subclass were determined by the Ouchterlony double immunodiffusion technique using a commercially available kit (The Binding Site Ltd.).
Virus. HRV2 was obtained from the MRC Common Cold Research Unit, Salisbury, U.K., grown in HeLa (OH5) cells and plaque-purified as previously reported (Appleyard et al., 1990) . Virus used for neutralization assays was stored as clarified tissue culture harvest in an equal volume of glycerol at -20 °C. For other immunoassays, virus was stored at -70 °C following concentration and purification. Briefly, virus was released from infected HeLa cells by two cycles of freezing and thawing after 24 h incubation at 34 °C. Cell debris was removed by low-speed centrifugation, and additions were made to the culture to provide final concentration of 25 mM-HEPES, 1% Sarkosyl (BDH) and 5 mM-EDTA prior to centrifugation at 80000g for 1 h. The virus pellet was resuspended in 2 ml 10 mM-Tris-HCl buffer pH 7.6, containing 10 mM-NaC1 and 0.1% 2-mercaptoethanol, and was sedimented into a 14 ml buffered (100 mM-Tris-HC1, 100 mN-NaC1, pH 7.6) 15 to 45 % sucrose gradient at 200000 g for 2 h. The density gradient was fractionated into 1 ml volumes, and peak virus concentration determined spectrophometrically at 259 nm.
Radiolabelled virus was prepared by infecting HeLa cells at high multiplicity and incubating at 34 °C for 1 h. The seed culture was decanted and the cell sheets were washed and re-fed with fresh complete medium and incubated for a further 3 h. The cells were then re-washed and re-fed twice with serum-and methionine-free medium with an interval of 1 h incubation at 34 °C between washes. Following the second re-feeding, 400 gCi of [3SS]methionine was added, and the cultures were incubated at 34 °C overnight. Thereafter, the virus was harvested, concentrated and purified as above.
ELISA techniques. Anti-peptide activity was determined by indirect ELISA. Peptides, diluted to 2 gg/ml in carbonate/bicarbonate buffer (15 mg-Na2CO a, 35 mM-NaHCO 3, pH 9.6) were used to coat flexible PVC microplates, air-dried at 37 °C and methanol-fixed. This was followed by successive additions of test sample and peroxidase-labelled anti-mouse antibody (1/1000, ICN Immunobiologicals), using PBS which contained 2 % skimmed milk powder as the diluent. The plates were thoroughly washed prior to each addition and incubated for at least l h at 37 °C afterwards. The tests were developed using ophenylene diamine/peroxide substrate in citrate buffer, stopped with 12.5 % sulphuric acid and absorbances read at 492 nm on a Titertek Multiskan spectrophotometer. Anti-virus activity was assessed by indirect sandwich ELISA, in which rabbit anti-HRV2 IgG (1/800) was bound to microplates and used to capture purified virus particles at a concentration of 2 gg/ml. Subsequent stages of the test were the same as those of the indirect ELISA. Titres were calculates as the log10 reciprocal antibody dilution producing 50% of the maximum absorbance plateau value (loga0 Pmaxs0).
Neutralization assay. This was performed using a two-dimensional microneutralization technique similar to that described by Booth et al. (1978) . Briefly, doubling dilutions of antibody were reacted with halflogx0 dilutions of virus for 2 h, HeLa cells were added as indicators of residual infectivity and the microplates were incubated at 34 °C for 5 days prior to fixing and staining. Antibody titres were calculated as the loga0 reciprocal antibody dilution required for 50% neutralization of 100 tissue culture infective units of virus (lOgl0 SNs0 / 100 TCIDs0 ) from regression analysis of the reciprocal antibody dilutions that neutralized 50 % of each virus dose.
Radioimmunoprecipitation assays (RIPA).
Small aliquots (10gl containing 5000 c.p.m.) of aSS-labelled virus particles were mixed with 100 gl samples of each MAb, serially diluted in NTE buffer (50 mMTris-HC1, 150 mM-NaC1, 5 mM-EDTA, 0.1% v/v NP40, pH 7.9) and placed at 4 °C overnight. For MAbs other than IgG, 10 gl of antimouse rabbit IgG (Serotec Ltd, 1/10) was then added and the mixtures were incubated at 37 °C for 1 h. This was followed by the addition of equal volumes of 1% (w/v) Protein A suspension (Pansorbin, Calbiochem) to all samples and maintenance at ambient temperature for I h. Precipitated immune complexes were pelleted by centrifugation, washed once and resuspended in 100 gl of NTE buffer. Precipitates and combined supernatants were each mixed with 5 ml of scintillation fluid (Liquiscint, National Diagnostics) for counting. The number of counts precipitated was calculated as a percentage of the total input radioactivity for each sample. Titres were determined as the log10 reciprocal antibody dilution of each MAb that precipitated 50 % of the counts (log10 CPMs0 ).
Functional affinity measurements. The RIPA technique was modified to estimate values for the binding affinity of MAbs to virus particles. In this method, modelled on that of Farr (1958) , 100 ~tl volumes of each MAb, diluted to the previously determined 50 % endpoint, were mixed with 10 ~tl volumes from a range of radiolabelled virus dilutions, of known antigen concentration, starting at 5000 c.p.m. Subsequent stages followed the procedure described for RIPA except that antimouse antibody was added to all reaction mixtures. The functional affinity value (L/mo1-1) for each MAb was calculated from combined Langmuir and Scatchard plot analyses of the precipitation data (Jackson et al., 1988) , based on an M r of 9 x 106 for rhinovirus particles.
Virus attachment assay. Density gradient-purified, radiolabelled particles were passed through a Sephadex G-100 to column to remove sucrose and were diluted 1/10 in PBS containing 2 % fetal calf serum. Equal volumes (500 lal) of the virus and MAbs were mixed and incubated at 37 °C for 1 h. Aliquots (200 gl) of the mixtures were transferred to each of four 25 cm ~ flasks of washed HeLa cell monolayers maintained at room temperature on a rocking platform. One flask was harvested at each time interval of 0, 10, 20 and 30 min in order to determine the percentage of viral attachment. Levels of unattached virus were estimated by thoroughly washing the cell sheets and counting the pooled washes in Liquiscint, and of attached virus by solubilizing the cell sheets with 98 % formic acid followed by drying onto glass fibre discs (Whatman GFA) and counting in Betafluor (National Diagnostics).
Results

Production of monoclonal anti-peptide antibodies
The immunogenicity of two peptides, representing HRV2 VP2 residues 156 to 170 synthesized in tandem with one or other of two T cell epitopes non-contiguous on the virion, was assessed by a dose-response study in BALB/c mice. Groups of animals were inoculated with either 200, 100, 50 or 25 lag of adjuvanted peptide per mouse, and the anti-peptide responses of individuals were determined at intervals over a 2 month period by indirect ELISA using a peptide corresponding to the B cell epitope alone. Anti-peptide responses were evident in animals of all groups. However, peptide 2 elicited similar high levels of antibody at all doses, whereas the serum titres of mice receiving 200 or 100 ~tg of peptide 1, which equalled those of mice inoculated with peptide 2, were appreciably higher than of those receiving 50 or 25 ~tg. There was no detectable antibody binding to peptides corresponding to the T cell epitopes alone.
Some of the animals with similar serum titres from the higher dose groups were inoculated a second time at various time intervals with slightly lower concentrations of unadjuvanted homologous peptide. The spleens were removed 3 days after, and splenocytes recovered for hybridoma formation. Several monoclonal hybrid lines, secreting antibody that recognized virus particles and/or peptide in screening ELISAs, were established from four fusions using spleen cells of mice immunized with peptide 1. None of these, however, was capable of precipitating or neutralizing the virus. Furthermore, of the 21 MAbs isotyped all but one were of the IgM class, the single exception being an IgG3. Because of the problem of high non-specific reactivity often associated with IgM antibodies, only four of these MAbs (501,504, 508 and 509) were used in characterization studies. In contrast, the fusion of spleen cells from animals inoculated with peptide 2 resulted in the isolation of monoclonal lines secreting specific antibody of several isotypes (Table 1) , 22 of which were used for further detailed characterization.
Specificity of anti-peptide MAbs
Twenty-six MAbs were characterized by titrations in ELISA against a peptide representing the VP2 B cell epitope and antibody-captured virus, in RIPA against native and heat-treated (60 °C for 1 h) radiolabelled virus particles and in neutralization assays. The results, summarized in Table 1 , show that the MAbs can be categorized into four major groups on the basis of their reactions, as follows. First, group 1 consists of three MAbs that had high titres in all the assays. Group 2 consists of three MAbs that bound well to all the test antigens in ELISA and RIPA, but did not measurably neutralize virus infectivity. The addition of anti-mouse IgG resulted in significant virus neutralization by only one MAb (P004) from this group. Group 3 contains ten MAbs that reacted significantly only with peptide and untreated virus in ELISA and heated particles in RIPA. Four of these, however, consistently demonstrated a slight ability to precipitate native particles at high antibody concentrations, although at insufficient levels to determine titres accurately, and these are consequently assigned to a subgroup 3 a. Finally, group 4 comprises the remaining 10 MAbs which were, in general, peptide-specific, although three had low level reactivity with heated particles in RIPA and thus constitute subgroup 4a.
Functional affinity measurements
The degree of binding to virus particles by anti-peptide MAbs from groups 1 and 2 was assessed by their precipitating ability and, as virions contain 60 potential 
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Functional affinity values within the range 3.8 x 101° to 8"6 x 1012 L/mo1-1 were obtained for the 10 antibodies (Table 2 ). There was no obvious correlation between these values and neutralizing ability, nor were there any marked differences between the values for anti-viral and anti-peptide MAbs.
Inhibition of virus attachment to cells
The effect of pre-reaction of radiolabelled HRV2
particles with antibodies on their subsequent ability to attach to HeLa cells was determined over 30 min. Two anti-peptide MAbs from each of groups 1 and 2 were compared with the 8F5 anti-viral MAb and an affinitypurified polyclonal antibody preparation against peptides of residues 156 to 170 (Hastings et al., 1990) . blocking by group 2 anti-peptide MAbs and, surprisingly, the neutralizing 8F5 anti-viral MAb (Fig.   1 ).
Discussion
Two peptides, representing the HRV2 VP2 sequence of residues 156 to 170, collinear with T cell epitopes derived from either VP1 (peptide 1) or VP2 (peptide 2) of the homologous virus, were used to immunize mice for MAb production. Peptide 1 induced MAbs that failed to precipitate or neutralize virus and were predominantly IgM (20 of 21 tested). This may have been a chance event, but raises the possibility that the peptide was deficient in its ability to stimulate the differentiation process of B cell development that leads to heavy chain switching from IgM to IgG secretion. If so, this implies that the efficiency of this process is related to the nature of the T cell epitope driving the B/T cell interaction. Previously it has been shown that the choice of T cell epitope can affect the antigen specificity of antibodies elicited by an FMDV B cell epitope when combined in a single peptide (Francis et al., 1987b) .
In contrast, peptide 2 induced MAbs with a range of isotypes, although there was a greater representation of IgA than might be expected from the normally low proportion of circulating IgA in mice. These clearly fell into four major groups of differing antigenic specificities. The most specific MAbs (group 4) mainly recognized synthetic peptides alone, although some bound weakly to heated virus. MAbs in group 3 bound to captured untreated virus in sandwich ELISA and were able to precipitate heat-treated particles (60 °C for 1 h), but did not precipitate native particles. These findings show that the virus is conformationally altered to expose novel antigenic determinants, either when heated or when captured with polyclonal antibody preparations, as reported for antibody-bound FMDV particles (McCullough et al., 1985) . In the case of rhinoviruses, heating at 60 °C is known to alter the sedimentation coefficient from 160S to 80S, consistent with their appearance as empty particles in electron micrographs. The ability of some group 4 MAbs to recognize heated, but not captured, virus indicates that the distorted conformations are not identical in the two cases. MAbs in the remaining two groups all recognized intact virus particles, judged by their capacity to precipitate them efficiently, but could be differentiated by their ability to neutralize (group 1) or not (group 2). The high proportion of MAbs found in this study that recognize both virus and peptide contrasts with a previous report by Ferguson et al. (1986) . This group raised approximately 250 MAbs to peptides representing an antigenic site on poliovirus type 3, but found that the vast majority were peptide-specific, and the two that bound to virus did not recognize immobilized peptide. Conversely, all of the anti-viral MAbs raised to HRV2 by Appleyard et al. (1990) were specific for virus particles (S. Russell, personal communication) as they were directed against conformational determinants. The only anti-HRV2 antibody that also bound peptide was the 8F5 MAb described by Skern et al. (1987) .
The majority of rhinovirus serotypes infect cells by an initial interaction of a common cell receptor (Colonno et al., 1986 ), ICAM 1 (Greve et al., 1989 Staunton et al., 1989) with a viral attachment site that is protected from immune surveillance by its location in a 'canyon' on the particle surface (Rossmann et al., 1985; Colonno et al., 1988) . HRV2, however, belongs to the minor cell receptor group of rhinoviruses (approximately 10 % ; Uncapher et al., 1991) for which the early stages of the infection process have not yet been elucidated. Nevertheless, the structural homology of viruses in the major and minor receptor groups (HRV14 and HRV1A, respectively; Rossman et al., 1985; Kim et al., 1989) suggests a similar location for the viral attachment site, albeit with different receptor specificity. Antibodies that bind around the rim of the canyon thus have the potential to neutralize virus by sterically preventing the contact between receptor and attachment sites. This indeed appears to be the principal mechanism by which our group 1 MAbs neutralize. They blocked viral attachment, and sequence alignment and structural analogy with HRV1A place the key amino acids involved in the MAb binding close to the southern lip of the canyon (P. V. Barnett & N. R. Parry, unpublished) . Furthermore, sucrose density gradient analyses of these MAbs when reacted with radiolabelled virus particles, under conditions of either antibody or antigen excess, failed to demonstrate any aggregation due to immune complex formation (data not shown). These findings only partially agree with those of Colonno et al. (1989) , who reported that anti-viral MAbs, which defined the equivalent NIMII site of HRV14, aggregated virus in addition to interfering with viral attachment to isolated cell membranes. Surprisingly, in our hands and under the same conditions employed for anti-peptide MAbs, the neutralizing anti-HRV2 MAb 8F5 (Skern et al., 1987) did not prevent viral attachment. As 8F5 recognizes an epitope comprising, in part at least, the same residues as the peptide neutralization epitopes, this suggests that the region of the VP2 peptide of residues 156 to 170 may be involved in neutralization by more than one mechanism.
The reason why MAbs in groups 1 and 2 differ so markedly in their neutralizing ability is not clear. Antibodies in both groups recognize intact virus particles with similar binding affinities, which contrasts with the study by Langedijk et al. (1991) of MAbs to peptides of human immunodeficiency virus type 1 and, moreover, peptide binding studies indicate that they recognize determinants containing the same amino acids (P. V. Barnett & N.R. Parry, unpublished) . One possible explanation for the difference in activity could lie in the orientation of bound antibody relative to the virus surface; neutralizing MAbs may be oriented towards the fivefold axis of symmetry thus overhanging the canyon, whereas non-neutralizing MAbs may be directed towards the threefold axis, away from the canyon. A second explanation may be that group 1 MAbs can induce conformational changes of the capsid, as demonstrated for polyclonal antibodies in this study, thereby possibly preventing its subsequent attachment to cells. However, this is unlikely since HRV2 particles captured in a sandwich ELISA with the group 1 MAb P024, unlike those captured by polyclonal antiserum, were not recognized by a biotinylated group 3 MAb P005 (data not shown). A third possibility involves the isotypes of the antibodies in group 1. The three neutralizing antipeptide MAbs are either IgA or IgM. The relative molecular masses of the IgA MAbs have been estimated to be well in excess of 200K by FPLC and Western blot analyses, indicative of the dimeric form. Multivalency and, therefore, larger molecular size may be a prerequisite for efficient neutralization with these MAbs, which could explain the difference in neutralizing activity between the IgM and the two IgA antibodies. This hypothesis is supported to some extent by studies with a pepsin digest fragment of MAb P024 (group 1, IgA), obtained using the technique described by Sharon & Givol (1976) . The fragment, with an M r of approximately 5'2K, consistent with Fv, bound to virus and had the same specificity for an overlapping series of peptides as the whole antibody molecule, but did not neutralize infectivity. The subsequent addition of anti-mouse antibody resulted in the restoration of neutralizing activity, but it was not possible to compare this quantitatively with the original undigested preparation. It is not clear whether the restoration of neutralization was due simply to increasing size of the binding complex or to the re-establishment of the potential for multivalent binding. The latter case would be analogous to previous reports that monovalent Fab fragments derived from neutralizing IgG antibodies to polio-and rhinovirus only neutralize after the addition of anti-antibody (Emini et al., 1983; Colonno et al., 1989) . The finding that the addition of anti-mouse antibody to our group 2 MAbs resulted only in low level neutralization in one case, however, argues against an absolute correlation between neutralization and multimeric binding. Conceivably, effective neutralization by anti-peptide antibodies may result from the appropriate combination of both antibody orientation and molecule size.
The immortalization of B cells from a single animal immunized with peptide resulted in the isolation of MAbs with four different specificities. A minority of these recognize intact virus, and a few also neutralize infectivity, in agreement with analyses of polyclonal antipeptide sera. Presumably the ratio of antibodies with these specificities varies in individual animals. This would explain both the inconsistency of neutralizing responses observed following injection with the same doses of immunogenic peptides and the difficulties experienced in correlating the results of assays measuring different properties of polyclonal antisera. Clearly it is desirable to manipulate peptides to increase the proportion of neutralizing antibodies elicited by them. Crystallization studies of neutralizing anti-peptide MAbs with virus and peptides could provide valuable information on the requirements of peptide design necessary to achieve this objective, and such studies are underway with the group 1 MAbs. Anti-peptide MAbs may also prove useful in the evaluation of novel presentation systems for synthetic antigens, particularly during the manipulation of immunogenic sequences that are not recognized by anti-viral MAbs in isolation because these sequences normally contribute to conformational sites, as in the case of poliovirus peptides (Ferguson et al., 1986) . In this context we have used the MAbs described here to compare the HRV2 sequence expressed at two locations on hepatitis B core antigen particles (Brown et al., 1991) . When this region was inserted into the immunodominant el loop of the core particles it was found to be five to 10 times more efficient at binding groups 1 and 2 MAbs than a similar insertion at the N terminus. This appeared to correlate with the results of comparative immunogenicity studies in which the loop construct elicited 10-to 50-fold greater antibody responses than the N terminus construct. Furthermore, three out of four peptide-specific (group 4) MAbs failed to recognize either construct.
